TrianglePUBLICATIONS · 37910822
First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- J Clin Oncol
- Publication date
- 2023 Dec 20
- First author
- Monk BJ
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Monk BJ
- type
- Author
- name
- Colombo N
- type
- Author
- name
- Tewari KS
- type
- Author
- name
- Dubot C
- type
- Author
- name
- Caceres MV
- type
- Author
- name
- Hasegawa K
- type
- Author
- name
- Shapira-Frommer R
- type
- Author
- name
- Salman P
- type
- Author
- name
- Yañez E
- type
- Author
- name
- Gümüş M
- type
- Author
- name
- Olivera Hurtado de Mendoza M
- type
- Author
- name
- Samouëlian V
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Monk BJ
- type
- Author
- name
- Colombo N
- type
- Author
- name
- Tewari KS
- type
- Author
- name
- Dubot C
- type
- Author
- name
- Caceres MV
- type
- Author
- name
- Hasegawa K
- type
- Author
- name
- Shapira-Frommer R
- type
- Author
- name
- Salman P
- type
- Author
- name
- Yañez E
- type
- Author
- name
- Gümüş M
- type
- Author
- name
- Olivera Hurtado de Mendoza M
- type
- Author
- name
- Samouëlian V
- type
- Author
- bibliography ids
- nci-bib-9e58f95c3f98075cef6de1a0
- book metadata
- content sha256
- ed1bec72b22d820567c12300c2c6ab5778cbfa230e7d593489356705641afd02
- document type
- citation
- dois
- 10.1200/JCO.23.00914
- electronic publication date
- display
- 2023 Nov 1
- precision
- day
- year
- 2023
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:37910822
- immutable id
- pubmed:37910822@ed1bec72b22d820567c12300c2c6ab5778cbfa230e7d593489356705641afd02
- journal
- abbreviation
- J Clin Oncol
- issn electronic
- 1527-7755
- issn print
- 0732-183X
- issue
- 36
- name
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- nlm unique id
- 8309333
- pages
- 5505-5511
- volume
- 41
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 37910822
- provenance
- batch id
- 6d213eecf21b6b7867cb
- provider
- NCBI PubMed ESummary
- record sha256
- ed17a1578630e6c18b564c76178bc5b4c8d330fc86dfc48bebfcfc351f1ace56
- response sha256
- 684f894a21d8f5f78a3bd0acd8ee4215ff94144487c53dab1056650ee8d6751d
- retrieved at
- 2026-09-09T23:48:19.049083+00:00
- publication date
- display
- 2023 Dec 20
- precision
- day
- year
- 2023
- publication types
- Journal Article
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.
Preserved source evidence · Not medical advice